SLN approach for nose-to-brain delivery of alprazolam

In the present study, alprazolam-loaded solid lipid nanoparticles were prepared and characterized. They were evaluated for their efficiency in nose-to-brain targeting and biodistribution in a suitable animal model after intranasal delivery. Solid lipid nanoparticles may offer an improvement to nose-to-brain drug delivery since they are able to protect the encapsulated drug from biological and/or chemical degradation. The distribution of the drug to different organs was recorded through biodistribution studies in male Wistar rats and gamma scintigraphy imaging in New Zealand rabbits by tagging the formulation with radioactive substance 99mTc. The radioactivity count of various organs was taken as a function of the drug concentration. The study reveals that alprazolam can be rapidly transferred to the brain via intranasal route, bypassing the blood–brain barrier and a direct nose-to-brain transfer. The enhanced rate and extent of transport may help in reducing the dose and dosing frequency, thereby providing ease for ambulatory patients.